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Background: Dobutamine stress contrast echo (DSCE) is a valuable adjunct in clinical practice for the assessment of the presence and extent of 
coronary artery disease (CAD). The aim of the current study was to evaluate the prognostic role of DSCE in patients with known or suspected CAD in 
different age groups.
Methods: We retrospectively studied 2653 (61.2 ± 9.9 years, male) consecutive patients who were referred to our department for clinically 
indicated DSCE. Ischemic response was defined as wall-motion deterioration and/or perfusion abnormality in two or more consecutive myocardial 
segments. Patients were divided into 3 groups according to their age: young adults (age<45yrs), middle-aged (45<age<65) and elderly (age>65). 
Mean follow-up lasted 5 ± 1.3years. End points included all-cause mortality, the occurrence of acute coronary syndrome, the need for late 
revascularization (>3 months) and hospitalizations.
Results: In 886 (33.8 %) patients, ischemic response to DSCE was illustrated, whereas the remaining patients had no abnormal finding during 
DSCE. During follow-up end-points were noted in 459 (17.3 %) patients. Logistic regression analysis revealed that DSCE response was the strongest 
predictor for adverse outcomes (O.R 5.1847, 1.7698 to 15.1891 95% C.I), especially for middle-aged patients. 5-year event-free proportion was 
0.670 ± 0.07 for ischemic responders, while for non-ischemic responders the respective rate was 0.909 ± 0.03, (p<0.05). Hazard ratio was 3.7879 
for patients with positive DSCE (1.5895 to 9.0272, 95% C.I).
Conclusion: Dobutamine stress contrast echo is a strong predictor of end points in patients with known or suspected CAD, especially for middle-
aged patients.
